A recent study examined the impact of a nightly dose of pediatric prolonged-release melatonin on sleep disturbances in children with autism spectrum disorder.
A nightly dose of pediatric prolonged-release melatonin (PedPRM) administered to children with autism spectrum disorder (ASD) moderated sleep disturbances, a trial in 80 children and adolescents from 2 to 17 years of age with ASD found. Participants had experienced at least 3 months of impaired sleep, defined as sleeping continuously for fewer than 6 hours or taking more than a half hour to fall asleep most nights. Before entering the study, all participants had tried standardized sleep hygiene and behavioral interventions.
The study comprised a 2-week placebo run-in followed by a randomized trial during which participants in the intervention group received a nightly dose of PedPRM (2 mg, 5 mg, or 10 mg) 30 to 60 minutes before bedtime for up to 104 weeks (most children were treated for 2 years). This was followed by a 2-week placebo period to assess withdrawal effects.
PedPRM was associated with improvements in participants’ sleep and caregiver satisfaction with their child’s sleep patterns, quality of sleep, and quality of life, benefits that were maintained throughout the treatment period, though they declined somewhat during the placebo phase. The most common treatment-related adverse events were fatigue (experienced by 6.3% of participants), somnolence (6.3%), and mood swings (4.2%). PedPRM was not associated with any detrimental effects on growth or pubertal development (Malow, BA et al. J Am Acad Child Adolesc Psychiatry. 2020. Epub ahead of print).
Thoughts from Dr. Farber
Melatonin has been a lifesaver for many parents, markedly improving quality of life, especially those whose children have developmental disabilities. Previously, at times I had been forced to use chloral hydrate. This study, while not exploring some possible side effects (eg, lab abnormalities), does support that melatonin can be used safely, in high doses, for at least two years.
Yamo enrolls final patient of phase 2 study of L1-79 to treat symptoms of ASD
November 29th 2023Yamo Pharmaceuticals has initiated a phase 3 readiness program for L1-79, following the enrollment of its final patient in a phase 2 study evaluating the autism spectrum disorder (ASD) treatment for patients aged 2 to 21 years.
Meet the Board: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI
May 20th 2022Contemporary Pediatrics sat down with one of our newest editorial advisory board members: Vivian P. Hernandez-Trujillo, MD, FAAP, FAAAAI, FACAAI to discuss what led to her career in medicine and what she thinks the future holds for pediatrics.
Discussing software that helps track progress after an autism diagnosis
October 27th 2023In this interview with Contemporary Pediatrics®, Lauren Lanzon, MSW, MA, BCBA, clinical trainer, Carolina Behavioral Innovations, explains how technology and software is helping families following an autism diagnosis in their child.
Meet the board: Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN
April 22nd 2022In the latest episode of our podcast series, Jessica L. Peck, DNP, APRN, CPNP-PC, CNE, CNL, FAANP, FAAN shares why she got into medicine, the myths of pediatric, and what the future may hold for the specialty.
Exome sequencing should be used for diagnosing cerebral palsy
October 13th 2023A systematic review and meta-analysis found that such sequencing indeed has an equivalent high genetic diagnostic yield in cerebral palsy, which supports including this neurodevelopmental disorder among those for which diagnostic exome sequencing should be used.
Is ADHD associated with shorter-than-expected height?
October 10th 2023To assess the role of familial factors, investigators analyzed data for a family-based group created from another Swedish national register that included 833,172 individuals without ADHD with different levels of relatedness to the individuals with ADHD and a group of matched controls.